CA 19-9 measurement

Ventrucci M, Cipolla A, Racchini C, et al: Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49(7-8):1149-55.

Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.. J Clin Oncol. 2001; 19:1865-78.

Safi F, Beger HG, Bittner R, et al: CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57(4):779-83.

Slesak B, Harlozinska-Szmyrka A, Knast W, et al: Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000; 89(1):83-8.

Vestergaard EM, Hein HO, Meyer H, et al: Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clinical Chemistry 1999; 45(1):54-61.

Ritts RE & Pitt HA: CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998; 7(1):93-101.

Sperti C, Pasquali C, Guolo P, et al: Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Cancer 1996; 78(2):237-43.

Del Favero G, Fabris C, Plebani M, et al: CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986; 57(8):1576-9.

Putzki H, Student A, Jablonski M, et al: Comparison of the tumor markers CEA, TPA, and CA 19-9 in colorectal carcinoma. Cancer 1987; 59(2):223-6.